Good morning, everyone, and how are you today? We are doing just fine, thank you, despite a steady downpour that is making for a soggy feeling at the Pharmalot campus. Nonetheless, our spirits are sunny. How so? We will remind you of a favorite saying of the Morning Mayor: Every brand new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will brew another cup of stimulation and forage for items of interest. Speaking of which, here are a few. Hope your journey goes well and, as always, do keep in touch. …

GlaxoSmithKline (GSK) plans to team with some of the nation’s most prominent CRISPR researchers to use the gene-editing technology in a search for new drugs, establishing a new lab in San Francisco and spending up to $67 million over five years, STAT reports. Jennifer Doudna, the University of California, Berkeley, researcher who co-invented the CRISPR enzyme technology, will help lead the effort, along with Jonathan Weissman, a UC San Francisco researcher who has been using CRISPR to understand the function of individual human genes and how they work together.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might observe that Mr Trump would be wiser to reserve his role in any negotiations to be “The Closer” – but then again, if he owns the process of the deal, mayhaps he will be less likely to call it “terrible” at the final moment? We shall see.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy